Skip to main content

Pregabalin Disease Interactions

There are 6 disease interactions with pregabalin.


Anxiolytics/sedatives/hypnotics (applies to pregabalin) drug dependence

Major Potential Hazard, Moderate plausibility. Applicable conditions: Drug Abuse/Dependence

Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms. In patients who have developed tolerance, overdosage can still produce respiratory depression and death. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible. Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents. In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients. After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.


  1. Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994): 1721-2
  2. Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993): 374-5
  3. "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.
  4. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca, Plattsburg, NY.
  5. "Product Information. Sonata (zaleplon)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
  6. "Product Information. Equanil (meprobamate)." Wallace Laboratories, Cranbury, NJ.
  7. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical, Abbott Park, IL.
View all 7 references

Antiepileptics (applies to pregabalin) suicidal tendency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Psychosis

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs across multiple indications in either monotherapy or adjunctive therapy for a median treatment duration of 12 weeks (up to a maximum of 24 weeks) showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. The estimated rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% for 16,029 placebo-treated patients, representing an increase of approximately 1 case for every 530 patients treated. There were 4 suicides in AED-treated patients and none in placebo-treated patients, although the number is too small to establish any causal relationship. The increased risk of suicidal thoughts or behavior was observed as early as 1 week after starting AEDs and persisted for the duration of treatment assessed. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Therapy with AEDs should be administered cautiously in patients with depression or other psychiatric disorders. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. For clinically significant or persistent symptoms, a dosage reduction or treatment withdrawal should be considered. If patients have symptoms of suicidal ideation or behavior, treatment should be discontinued.


Pregabalin (applies to pregabalin) angioedema

Moderate Potential Hazard, Moderate plausibility.

Angioedema has been reported during pregabalin therapy, including reports of life-threatening angioedema with respiratory compromise requiring emergency treatment. Therapy with pregabalin should be administered cautiously in patients at risk of developing angioedema or those with a previous episode of angioedema.


Pregabalin (applies to pregabalin) creatine kinase elevations

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Myopathy

The use of pregabalin has been associated with creatine kinase elevations. Use caution when treating patients with diagnosed of suspected myopathy or with significantly elevated creating kinase levels.


Pregabalin (applies to pregabalin) peripheral edema

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure

Pregabalin treatment may cause peripheral edema. There are limited data concerning the use of pregabalin in patients with congestive heart failure. Therapy with pregabalin should be administered cautiously in patients with New York Heart Association (NYHA) Class III or IV cardiac status.


Pregabalin (applies to pregabalin) PR interval prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Block, Abnormal Electrocardiogram

Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation. In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day. This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block. Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications. However, these analyses cannot be considered definitive because of the limited number of patients in these categories.

Pregabalin drug interactions

There are 279 drug interactions with pregabalin.

Pregabalin alcohol/food interactions

There is 1 alcohol/food interaction with pregabalin.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.